Administration RoutesEvidence & Dosage
Subcutaneous, intramuscular, nasal, oral, topical — bioavailability and safety.
Evidence at a glance
- Total studies
- 974
- With abstract
- 8
- Meta / Systematic / RCT
- 1
- Highly cited
- 2
- Publication years
- 1949–2026
Administration Routes in the context of Peptides
This topic is part of our "Peptides" world. There you'll find methodology, evidence and the highest-impact levers — plus the order in which they sensibly build on each other.
Go to PeptidesTop studies on Administration Routes
Ranked by influential-citation count and publication year.
A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.
Neuropsychopharmacology2002RCT30 influential citationsAcamprosate and naltrexone have each demonstrated safety and efficacy for alcohol dependence in placebo-controlled clinical trials. There is scientific and clinical interest in evaluating these drugs in combination, given their high…
Comparative pharmacokinetic analysis of curcumin and curcumin O-glucuronide through curcumin nano-gel-based delivery system using liquid chromatogram tandem mass spectrometry.
Pak J Pharm Sci2026Study<h4>Background</h4>Curcumin exhibits limited oral bioavailability owing to its poor solubility and rapid metabolism.<h4>Objectives</h4>To develop a novel curcumin nano-gel (CNG) and evaluate its pharmacokinetics following oral and rectal…
Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.
Critical care medicine2018Objective: To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU. Design: Thirty-two international experts, four methodologists, and four critical…
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
MMWR Recommendations and Reports2016This guideline provides recommendations for primary care clinicians who are prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses 1) when to initiate or…
Pharmacokinetics of a novel formulation of ivermectin after administration to goats
American Journal of Veterinary Research2006<h4>Objective</h4>To evaluate the pharmacokinetics of a novel commercial formulation of ivermectin after administration to goats.<h4>Animals</h4>6 healthy adult goats.<h4>Procedure</h4>Ivermectin (200 microg/kg) was initially administered…
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Annals of the Rheumatic Diseases2013In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively)…
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Annals of the rheumatic diseases2023<h4>Objectives</h4>To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field.<h4>Methods</h4>An international task force was formed and solicited three…
CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports2022n=14This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016…
More topics in Peptides
Peptides Overview
Peptides, BPC-157, TB-500, safety and the state of the evidence.
Autoimmunity Risk
Immune modulation can both promote tolerance and tip into dysregulation.
BPC-157
Peptide for tissue regeneration, healing, and athletic recovery.
Cerebrolysin
A pig-brain peptide mix, stroke studies, not approved in Germany.
CJC-1295
GHRH analog, half‑life variants and pulse patterns.
Dihexa
Angiotensin derivative, cognitive/neuroplasticity signals in animal models.
GHK-Cu
Copper peptide for skin health, anti-aging, and wound healing.
GHRP-2
GH releaser, older generation, appetite stimulation as a side effect.
GHRP-6
GH releaser with a strong appetite component.
GLP-1 Rebound
Weight regain after stopping without lifestyle anchors.
GLP-1 Side Effects
Nausea, gastric emptying, muscle loss, pancreatitis risk.
Hexarelin
GH releaser, fast tolerance build-up, cardiac signals.
IGF-1 LR3
Modified IGF-1 with a long half-life — hypertrophy, the cancer-risk debate.
Immune Modulation
Automatisch via Trend Scout entdeckt. Supplements targeting inflammation and immune resilience remain a central research area.. PubMed: 11956 Ergebnisse.
Injection Safety
Sterile technique, bacteriostatic water, skin disinfection — a medical topic.
Ipamorelin
Selective GH releaser, cortisol‑sparing, and stack combinations.
KPV
An alpha-MSH fragment — anti-inflammatory, gut, skin, early research.
Liraglutide
First-generation GLP-1 for diabetes/obesity — daily, smaller effect size.
LL-37
Antimicrobial peptide, wound healing, immune modulation, early research.
MK-677
Ghrelin mimetic, not strictly a peptide — sleep, appetite, glucose risk.
Related topics from other worlds
ApoB
A better cardiovascular risk metric than LDL-C — modern lipidology.
Collagen
Skin, joints, tendons — evidence favors hydrolysate plus vitamin C.
Glucosamine
Joints, UK Biobank mortality study, sulfate vs HCl forms.
Microbiome Tests
What they can and can't do today — clinical relevance still limited.
Rapamycin
mTOR inhibition, longevity studies, off‑label dosing, and safety.
Telomeres
Chromosome ends, telomerase, lifestyle influences, the critical marker debate.